An exploratory analysis of KEYNOTE-062 data in patients with untreated advanced G/GEJ cancer showed a survival benefit with pembrolizumab compared with chemotherapy in a subgroup of patients whose tumors were MSI-H and PD-L1 CPS ≥ 1 (n = 33; median OS: not reached vs. 8.5 months; HR: 0.29; 95% CI: 0.11–0.81) [85]. This evidence concerns the gene CD274 and cancer.